Infants in Florida Have RSV Protection Options

As the respiratory syncytial virus (RSV) season expands in the state of Florida, the most significant US real-world study of a single-dose long-acting antibody designed to help prevent RSV lower respiratory tract disease in infants successfully met both of its co-primary endpoints.

The full results from the "Effectiveness of nirsevimab against RSV and RSV-related events in infants" study have been published in PEDIATRICS®, an official journal of the American Academy of Pediatrics, on July 22, 2025.

Ayman Chit, Head of North America Medical, Vaccines, Sanofi, commented in a press release, "These results support BEYFORTUS (nirsevimab) as a groundbreaking advancement in infant RSV disease prevention."

"With more than 40 real-world evidence studies to date, this latest study further strengthens the well-established body of data that shows that BEYFORTUS protects against RSV disease to help safeguard the health of all babies, regardless of whether they are born before or during the RSV season."

According to the Florida Department of Health, RSV is a common respiratory virus that typically causes mild, cold-like symptoms. Young children and older adults, especially those with certain underlying health conditions, are at higher risk for severe illness from RSV.

Florida’s RSV season is longer than that of the rest of the nation and exhibits distinct regional patterns. For this reason, the state is broken up into five RSV regions, each with its own RSV season.